Making the cut with PAMless CRISPR-Cas enzymes

Kathleen A Christie; Benjamin P Kleinstiver

doi:10.1016/j.tig.2021.09.002

Making the cut with PAMless CRISPR-Cas enzymes

Trends Genet. 2021 Dec;37(12):1053-1055. doi: 10.1016/j.tig.2021.09.002. Epub 2021 Sep 22.

Authors

Kathleen A Christie¹, Benjamin P Kleinstiver²

Affiliations

¹ Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA; Department of Pathology, Harvard Medical School, Boston, MA, 02115, USA.
² Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA; Department of Pathology, Harvard Medical School, Boston, MA, 02115, USA. Electronic address: bkleinstiver@mgh.harvard.edu.

Abstract

Genome editing technologies simplify our ability to rewrite genetic blueprints of life. However, CRISPR-Cas enzymes found in nature can only manipulate a fraction of the genome. To overcome this limitation, new Cas variants have been developed that unlock nearly the entire genome for editing.

Keywords: CRISPR; PAM; genome editing; targeting range.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

CRISPR-Cas Systems* / genetics
Gene Editing*

Abstract

Publication types

MeSH terms

Grants and funding